查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1692316

兒童神經母細胞瘤治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按治療類型、按最終用戶、按地區和競爭細分，2020-2030 年預測

Pediatric Neuroblastoma Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By End-User, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球兒童神經母細胞瘤治療市場價值為 14.5 億美元，預計在預測期內將出現令人印象深刻的成長，到 2030 年的複合年成長率為 8.58%。兒童神經母細胞瘤是一種主要影響幼兒的癌症，通常發生在嬰兒和幼兒身上，但偶爾也會發生在年齡較大的兒童身上。它起源於身體各部位的未成熟神經細胞（神經母細胞），最常見的是位於腎臟頂部的腎上腺。然而，它也可能出現在交感神經系統的其他部位，包括胸部、腹部和骨盆。神經母細胞瘤的症狀取決於腫瘤的大小、位置以及是否擴散。常見症狀可能包括腹部腫脹，疼痛，腫塊或腫塊，體重減輕，食慾不振，骨痛，煩躁，發燒和眼睛變化（如眼瞼下垂或瞳孔大小不等）。診斷通常需要結合多種影像檢查，例如超音波、CT 掃描和 MRI 掃描，以定位和評估腫瘤。還可以進行活體組織切片和骨髓抽吸以確認診斷並確定腫瘤的侵襲性。例如，根據美國臨床腫瘤學會 (ASCO) 的數據，神經母細胞瘤是美國兒童第三大常見癌症，佔所有兒童癌症病例的 6%。預計這種高發病率將推動對先進有效治療方案的需求，以改善被診斷患有神經母細胞瘤的兒童的治療結果。

市場概況
預測期 2026-2030
2024 年市場規模 14.5 億美元
2030 年市場規模 23.6 億美元
2025-2030 年複合年成長率 8.58％
成長最快的領域 化療
最大的市場 北美洲

主要市場促進因素

兒童神經母細胞瘤發生率上升

主要市場挑戰

毒性和長期影響

主要市場趨勢

盡量減少輻射

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：全球兒童神經母細胞瘤治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療類型（化療、免疫療法、放射療法等）
    • 按最終使用者（醫院、專科診所和其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第 6 章：亞太地區兒童神經母細胞瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 7 章：歐洲兒童神經母細胞瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 8 章：北美兒童神經母細胞瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 墨西哥
    • 加拿大

第 9 章：南美洲兒童神經母細胞瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲兒童神經母細胞瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 13 章：全球兒童神經母細胞瘤治療市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

  • United Therapeutics Corporation,
  • APEIRON Biologics AG
  • Baxter International Inc.,
  • Cell Ectar Biosciences Inc.
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • Bayer AG
  • Provectus Biopharmaceuticals Inc.
  • Sartorius AG
  • , Amgen Inc.

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 18782

Global Pediatric Neuroblastoma Treatment Market was valued at USD 1.45 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.58% through 2030. Pediatric Neuroblastoma is a type of cancer that primarily affects young children, usually occurring in infants and toddlers but occasionally in older children. It arises from immature nerve cells (neuroblasts) that are found in various areas of the body, most commonly in the adrenal glands, which sit on top of the kidneys. However, it can also develop in other parts of the sympathetic nervous system, including the chest, abdomen, and pelvis. The symptoms of neuroblastoma vary depending on the tumor's size, location, and whether it has spread. Common symptoms may include abdominal swelling, pain, a lump or mass, weight loss, loss of appetite, bone pain, irritability, fever, and changes in the eyes (such as drooping eyelids or unequal pupil size). Diagnosis often involves a combination of imaging tests, such as ultrasound, CT scans, and MRI scans, to locate and evaluate the tumor. Biopsy and bone marrow aspiration may also be performed to confirm the diagnosis and determine the tumor's aggressiveness. For instance, according to the American Society of Clinical Oncology (ASCO), neuroblastoma is the third most prevalent cancer among children in the U.S., representing 6% of all childhood cancer cases. This high incidence is expected to drive demand for advanced and effective treatment options to improve outcomes for children diagnosed with neuroblastoma.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.45 Billion
Market Size 2030USD 2.36 Billion
CAGR 2025-20308.58%
Fastest Growing SegmentChemotherapy
Largest MarketNorth America

Key Market Drivers

Rising Incidence of Pediatric Neuroblastoma

Growing awareness among healthcare providers and the public about the signs and symptoms of pediatric neuroblastoma has led to earlier diagnosis. As more cases are detected at an earlier stage, there is a greater need for timely and effective treatment. For instance, according to a 2025 study titled Global and Regional Trends in Paediatric Neuroblastoma Incidence and Mortality, 1990-2021: An Inequality and Projection Analysis, the global age-standardized death rate for pediatric neuroblastoma increased from 0.19 (95% UI, 0.16-0.23) in 1990 to 0.21 (95% UI, 0.14-0.28) per 100,000 population in 2021, with an estimated annual percentage change (EAPC) of 0.2. Regionally, mortality and incidence rates were highest in low-to-middle Social Development Index (SDI) regions, while Oceania recorded the lowest rates. Improved diagnostic techniques, such as genetic testing and advanced imaging, have made it easier to identify neuroblastoma cases accurately. This early detection allows for prompt intervention and treatment. The general growth in the global population, including the pediatric population, naturally leads to an increase in the number of neuroblastoma cases. While the exact causes of neuroblastoma remain unclear, some environmental and genetic factors may contribute to its development. As these factors continue to be studied, it may become possible to identify at-risk populations more effectively. The rising incidence of neuroblastoma has prompted increased research into potential treatments. Clinical trials and research efforts are essential in developing new therapies, which, in turn, drive the demand for Pediatric Neuroblastoma Treatment. The development of more effective and less toxic treatment options has improved the chances of successful outcomes for neuroblastoma patients. This has increased the demand for these treatments as they become more accessible. Advances in supportive care for pediatric cancer patients have improved overall treatment experiences and outcomes. As the quality of care continues to improve, more families seek treatment for their children. Improved access to healthcare services in various regions around the world means that more children with neuroblastoma are receiving appropriate treatment. This factor will help in the development of the Global Pediatric Neuroblastoma Treatment Market.

Key Market Challenges

Toxicity and Long-Term Effects

The standard treatments for pediatric neuroblastoma, which often include chemotherapy, radiation therapy, and surgery, can cause severe side effects in young patients. These treatments may damage healthy tissues and organs in addition to targeting cancer cells. The toxicity can result in short-term complications, such as nausea, fatigue, and hair loss, which can significantly impact a child's quality of life during treatment. Beyond the immediate treatment period, pediatric neuroblastoma survivors may face long-term health issues and late effects of treatment. These can include developmental delays, growth problems, hormonal imbalances, organ dysfunction, and an increased risk of secondary cancers. Monitoring and managing these long-term health issues require ongoing medical care and support. The toxicity and long-term effects of treatment can affect a child's physical and emotional well-being, as well as their ability to engage in normal childhood activities. This can have a lasting impact on their quality of life and overall development. Pediatric neuroblastoma and its treatment can take a toll on the psychological well-being of both patients and their families. Coping with treatment-related toxicity and long-term effects can be emotionally challenging, requiring psychosocial support and mental health services. Pediatric neuroblastoma survivors often require specialized survivorship care to address the unique health issues that may arise years after treatment. Access to comprehensive follow-up care and support services is essential to managing these long-term effects effectively. Finding the right balance between delivering effective treatment and minimizing toxicity is a complex challenge in pediatric neuroblastoma care. Oncologists must make treatment decisions that maximize the chances of a cure while minimizing potential harm.

Key Market Trends

Minimizing Radiation

Radiation therapy, while effective in treating neuroblastoma, can cause long-term side effects, especially in pediatric patients. These side effects may include growth abnormalities, developmental delays, and an increased risk of secondary cancers. Minimizing radiation aims to mitigate these risks. Innovations in radiation therapy techniques, such as intensity-modulated radiation therapy (IMRT) and proton therapy, allow for more precise targeting of cancer cells while sparing nearby healthy tissues. This precision reduces the potential for collateral damage and long-term toxicity. Radiation oncologists are increasingly tailoring treatment plans to each patient's specific needs and tumor characteristics. This individualized approach ensures that the minimum necessary radiation dose is used while maximizing therapeutic benefits. Minimizing radiation is often achieved through combination therapies. For instance, using chemotherapy or surgery to shrink tumors before radiation may allow for lower radiation doses and less toxicity. Risk stratification of neuroblastoma patients helps determine the appropriate level of treatment intensity. Low-risk patients may receive less aggressive therapy, including reduced radiation, to minimize long-term effects. Ongoing clinical trials are exploring novel treatment approaches that may reduce the reliance on radiation therapy or allow for lower radiation doses. These trials aim to maintain or improve treatment outcomes while minimizing toxicity. As more children with neuroblastoma survive into adulthood, there is a growing emphasis on long-term survivorship care. Minimizing radiation plays a role in reducing the late effects of treatment and improving the quality of life for survivors.

Key Market Players

  • United Therapeutics Corporation
  • APEIRON Biologics AG
  • Baxter International Inc.
  • Cell Ectar Biosciences Inc.
  • Pfizer Inc.
  • Bayer AG
  • Provectus Biopharmaceuticals Inc.
  • Sartorius AG
  • Amgen Inc.
  • F. Hoffmann-La Roche AG

Report Scope:

In this report, the Global Pediatric Neuroblastoma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pediatric Neuroblastoma Treatment Market, By Treatment Type:

  • Chemotherapy
  • Immunotherapy
  • Radiation Therapy
  • Others

Pediatric Neuroblastoma Treatment Market, By End-User:

  • Hospitals
  • Specialty clinics
  • Others

Pediatric Neuroblastoma Treatment Market, By region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Neuroblastoma Treatment Market.

Available Customizations:

Global Pediatric Neuroblastoma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pediatric Neuroblastoma Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy, and Others)
    • 5.2.2. By End-User (Hospitals, Specialty Clinics and Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Pediatric Neuroblastoma Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By End-User
    • 6.2.3. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Pediatric Neuroblastoma Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By End-User
    • 6.3.2. India Pediatric Neuroblastoma Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By End-User
    • 6.3.3. Australia Pediatric Neuroblastoma Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By End-User
    • 6.3.4. Japan Pediatric Neuroblastoma Treatment Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Treatment Type
        • 6.3.4.2.2. By End-User
    • 6.3.5. South Korea Pediatric Neuroblastoma Treatment Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Treatment Type
        • 6.3.5.2.2. By End-User

7. Europe Pediatric Neuroblastoma Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By End-User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Pediatric Neuroblastoma Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By End-User
    • 7.3.2. Germany Pediatric Neuroblastoma Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By End-User
    • 7.3.3. Spain Pediatric Neuroblastoma Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By End-User
    • 7.3.4. Italy Pediatric Neuroblastoma Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By End-User
    • 7.3.5. United Kingdom Pediatric Neuroblastoma Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By End-User

8. North America Pediatric Neuroblastoma Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By End-User
    • 8.2.3. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Pediatric Neuroblastoma Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By End-User
    • 8.3.2. Mexico Pediatric Neuroblastoma Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By End-User
    • 8.3.3. Canada Pediatric Neuroblastoma Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By End-User

9. South America Pediatric Neuroblastoma Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By End-User
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Pediatric Neuroblastoma Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By End-User
    • 9.3.2. Argentina Pediatric Neuroblastoma Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By End-User
    • 9.3.3. Colombia Pediatric Neuroblastoma Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By End-User

10. Middle East and Africa Pediatric Neuroblastoma Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By End-User
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Pediatric Neuroblastoma Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By End-User
    • 10.3.2. Saudi Arabia Pediatric Neuroblastoma Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By End-User
    • 10.3.3. UAE Pediatric Neuroblastoma Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Pediatric Neuroblastoma Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. United Therapeutics Corporation,
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. APEIRON Biologics AG
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Baxter International Inc.,
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. Cell Ectar Biosciences Inc.
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. Pfizer Inc.
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. F. Hoffmann-La Roche AG
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. Bayer AG
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. Provectus Biopharmaceuticals Inc.
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Sartorius AG
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10., Amgen Inc.
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer